focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 32.40
Ask: 32.90
Change: 0.00 (0.00%)
Spread: 0.50 (1.543%)
Open: 32.60
High: 33.50
Low: 32.20
Prev. Close: 33.00
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Announcement under rule 2.4 of the Takeover Code

24 Aug 2015 07:01

RNS Number : 8156W
EKF Diagnostics Holdings PLC
24 August 2015
 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

This is an announcement falling under Rule 2.4 of the Takeover Code and does not constitute an announcement of a firm intention to make an offer under Rule 2.7 of the Takeover Code. There can be no certainty that an offer will be made nor as to the terms on which any offer might be made.

 

24 August 2015

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Announcement under rule 2.4 of the City Code on Takeovers and Mergers

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, notes the recent press speculation and announces that further to the previous announcements of two non-binding preliminary proposals for its Point-of-Care business, it has received a highly preliminary approach from Jinjing (Group) Co., Ltd ("Jinjing") regarding a possible offer for the entire issued and to be issued share capital of the Company. There is no certainty that this approach will lead to an offer being made for the Company, nor as to the terms on which any offer may be made.

 

Rule 2.6(a) of the City Code on Takeovers and Mergers (the "Code") requires Jinjing by not later than 5pm p.m. on 20 September 2015 (the "relevant deadline"), either to announce a firm intention to make an offer for EKF in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. The relevant deadline will only be extended with the consent of The Takeover Panel in accordance with Rule 2.6(c) of the Code.

 

Pursuant to Rule 2.10 of the Code the Company confirms that there are 422,057,074 ordinary shares of 1p in issue with International Securities Identification Number GB0031509804.

 

A further announcement will be made as appropriate.

 

A summary is set out below of the dealing disclosure requirements under the Takeover Code, which require action by holders of 1 per cent. or more of the Company's issued share capital.

 

In accordance with Rule 30.4 of the Code, a copy of this announcement will be available on the Company's website www.ekfdiagnostics.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

 

Enquiries:

 

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

David Evans, Executive Chairman

Mob: 07740 084 452

Julian Baines, CEO 

Mob: 07788 420 859

Paul Foulger, CFO

Mob: 07710 989 255

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Robert Naylor (Corporate Finance)

Paul Fincham (Corporate Finance)

Walbrook PR Limited 

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Dealing Disclosure Requirements

 

Under Rule 8.3(a) of the Takeover Code, any person who is interested in 1 per cent or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8 of the Takeover Code. A Dealing Disclosure by a person to whom Rule 8.3(b) of the Takeover Code applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3 of the Takeover Code.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of the Takeover Code).

 

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDPGUGCRUPAGBW
Date   Source Headline
31st Aug 20182:00 pmRNSUpdate regarding proposed IPO of Renalytix AI
16th Aug 20187:00 amRNSHolding(s) in Company
9th Aug 20187:14 amRNSTrading update
9th Aug 20187:00 amRNSDiaSpect Tm McKesson US distribution agreement
8th Aug 20184:09 pmRNSHolding(s) in Company
24th Jul 20188:45 amRNSUS distribution agreement for diabetes assay kit
19th Jul 20187:00 amRNSManufacturing partnership with Oragenics, Inc.
4th Jul 20183:15 pmRNSExploring funding options for Renalytix AI
7th Jun 20182:30 pmRNSHolding(s) in Company
1st Jun 201810:00 amRNSUpdate regarding Renalytix AI PLC
31st May 20187:00 amRNSLicence and collaboration agreement signed
8th May 20183:10 pmRNSResult of AGM
18th Apr 201810:36 amRNSPosting of AR and Accounts & Notice of AGM
9th Apr 20188:25 amRNSUS FDA approval for Diaspect Tm
21st Mar 20182:18 pmRNSHolding(s) in Company
14th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
11th Jan 20187:00 amRNSTrading update
29th Dec 20177:00 amRNSTotal Voting Rights
21st Dec 20177:00 amRNSShare cancellation
1st Dec 20177:00 amRNSTotal Voting Rights
7th Nov 20173:07 pmRNSHolding(s) in Company
2nd Nov 20179:18 amRNSConfirmation of share cancellation
1st Nov 20177:00 amRNSTotal Voting Rights
27th Oct 20175:05 pmRNSHolding(s) in Company
3rd Oct 20173:44 pmRNSCancellation of escrow shares PDMR dealing/buyback
21st Sep 201710:16 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSHalf-year Report
6th Sep 20171:41 pmRNSReduction of capital
31st Aug 20177:00 amRNSNotice of Results
10th Aug 20177:00 amRNSHolding(s) in Company
7th Aug 20179:45 amRNSHolding(s) in Company
27th Jul 201711:18 amRNSResult of General Meeting
19th Jul 20178:54 amRNSHolding(s) in Company
6th Jul 20177:00 amRNSTrading update
26th Jun 20177:00 amRNSNotice of GM
26th Jun 20177:00 amRNSCancellation of share options
10th May 201711:45 amRNSResult of AGM
10th May 20177:00 amRNSTrading Update & Structure Update
18th Apr 201712:00 pmRNSAnnual Financial Report
4th Apr 201710:55 amRNSHolding(s) in Company
21st Mar 20171:47 pmRNSDirector/PDMR Shareholding
21st Mar 201712:04 pmRNSHolding(s) in Company
20th Mar 20177:00 amRNSFinal Results
20th Mar 20177:00 amRNSUpdate
2nd Mar 20177:00 amRNSNotice of Results
22nd Feb 20177:00 amRNSChange of Nominated Adviser and Broker
9th Jan 20177:00 amRNSTrading update
7th Nov 20167:00 amRNSTrading update
7th Oct 20167:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.